Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...
meeting minutes from the U.S. Food and Drug Administration (FDA) supporting a supplemental NDA (sNDA) submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion ...
As a neurologist at the forefront of research into Alzheimer's disease, I have worked with people who have managed to stop ...
Your brain is hiding secrets about Alzheimer's, and it is not what you think. Discover how your mind could be playing tricks ...
the brain needs as much as 20 percent of the body's overall energy consumption despite contributing only about 2 percent of the body's weight." Long naps can be early sign of Alzheimer's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results